Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX / FOLFOX therapy of colorectal cancer liver metastases. - Klinger,M.; Eipeldauer,S.; Hacker,S. (Eur J Surg Oncol, 2009)